While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Research tells us that eating enough protein and staying physically active can be helpful in reducing the amount of non-fat ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

More and more people are taking weight loss injectables like Wegovy — but not everyone prescribed these drugs should have ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...